Cargando…
Serum cholesterol and the risk of developing hormonally driven cancers: A narrative review
Although cholesterol has been hypothesized to promote cancer development through several potential pathways, its role in the risk of developing hormonally driven cancer is controversial. This literature review summarizes evidence from the highest quality studies to examine the consistency and streng...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067100/ https://www.ncbi.nlm.nih.gov/pubmed/36444895 http://dx.doi.org/10.1002/cam4.5463 |
_version_ | 1785018396467789824 |
---|---|
author | Murdock, Dana J. Sanchez, Robert J. Mohammadi, Kusha A. Fazio, Sergio Geba, Gregory P. |
author_facet | Murdock, Dana J. Sanchez, Robert J. Mohammadi, Kusha A. Fazio, Sergio Geba, Gregory P. |
author_sort | Murdock, Dana J. |
collection | PubMed |
description | Although cholesterol has been hypothesized to promote cancer development through several potential pathways, its role in the risk of developing hormonally driven cancer is controversial. This literature review summarizes evidence from the highest quality studies to examine the consistency and strength of the relationship between serum cholesterol parameters and incidence of hormonally driven cancer. Articles were identified using EMBASE. Longitudinal observational studies published between January 2000 and December 2020 were considered for inclusion. The endpoint of interest was incident prostate, ovary, breast, endometrium, and uterine cancers. In total, 2732 reports were identified and screened; 41 studies were included in the review. No associations were found for ovarian cancer. Most endometrial cancer studies were null. The majority (76.9%) of studies reported no association between cholesterol and prostate cancer. Data on breast cancer were conflicting, associations limited, and effect sizes modest. Our results do not provide evidence for a clear association between cholesterol and different types of incident, hormonally driven reproductive cancers. Future studies should investigate the impact of lipid‐lowering therapy. |
format | Online Article Text |
id | pubmed-10067100 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100671002023-04-03 Serum cholesterol and the risk of developing hormonally driven cancers: A narrative review Murdock, Dana J. Sanchez, Robert J. Mohammadi, Kusha A. Fazio, Sergio Geba, Gregory P. Cancer Med REVIEWS Although cholesterol has been hypothesized to promote cancer development through several potential pathways, its role in the risk of developing hormonally driven cancer is controversial. This literature review summarizes evidence from the highest quality studies to examine the consistency and strength of the relationship between serum cholesterol parameters and incidence of hormonally driven cancer. Articles were identified using EMBASE. Longitudinal observational studies published between January 2000 and December 2020 were considered for inclusion. The endpoint of interest was incident prostate, ovary, breast, endometrium, and uterine cancers. In total, 2732 reports were identified and screened; 41 studies were included in the review. No associations were found for ovarian cancer. Most endometrial cancer studies were null. The majority (76.9%) of studies reported no association between cholesterol and prostate cancer. Data on breast cancer were conflicting, associations limited, and effect sizes modest. Our results do not provide evidence for a clear association between cholesterol and different types of incident, hormonally driven reproductive cancers. Future studies should investigate the impact of lipid‐lowering therapy. John Wiley and Sons Inc. 2022-11-29 /pmc/articles/PMC10067100/ /pubmed/36444895 http://dx.doi.org/10.1002/cam4.5463 Text en © 2022 Regeneron Pharmaceuticals, Inc. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | REVIEWS Murdock, Dana J. Sanchez, Robert J. Mohammadi, Kusha A. Fazio, Sergio Geba, Gregory P. Serum cholesterol and the risk of developing hormonally driven cancers: A narrative review |
title | Serum cholesterol and the risk of developing hormonally driven cancers: A narrative review |
title_full | Serum cholesterol and the risk of developing hormonally driven cancers: A narrative review |
title_fullStr | Serum cholesterol and the risk of developing hormonally driven cancers: A narrative review |
title_full_unstemmed | Serum cholesterol and the risk of developing hormonally driven cancers: A narrative review |
title_short | Serum cholesterol and the risk of developing hormonally driven cancers: A narrative review |
title_sort | serum cholesterol and the risk of developing hormonally driven cancers: a narrative review |
topic | REVIEWS |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067100/ https://www.ncbi.nlm.nih.gov/pubmed/36444895 http://dx.doi.org/10.1002/cam4.5463 |
work_keys_str_mv | AT murdockdanaj serumcholesterolandtheriskofdevelopinghormonallydrivencancersanarrativereview AT sanchezrobertj serumcholesterolandtheriskofdevelopinghormonallydrivencancersanarrativereview AT mohammadikushaa serumcholesterolandtheriskofdevelopinghormonallydrivencancersanarrativereview AT faziosergio serumcholesterolandtheriskofdevelopinghormonallydrivencancersanarrativereview AT gebagregoryp serumcholesterolandtheriskofdevelopinghormonallydrivencancersanarrativereview |